Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) targeting the PD‐1/PD‐L1 axis are the cornerstones for clear cell metastatic renal cell carcinoma (mRCC) management.1, 2. This evidence concerns the gene CD274 and clear cell renal carcinoma.